Home LiteratureArticle Details
PMID: 9790338 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome.

Annals of surgery ·Vol. 228 ·No. 4 ·1998-10-00 ·Pages 479-90

Klintmalm GB

Abstract

The objective of this study from the International Registry of Hepatic Tumors in Liver Transplantation is to analyze the impact of tumor characteristics on tumor recurrence and patient survival. Many attempts have been made to identify patients with hepatocellular carcinoma who can be treated successfully with liver transplantation. Studies presented to date lack enough patients to make reported findings universally accepted. In lieu of a prospective, randomized multicenter trial, in 1992 an International Registry of Hepatic Tumors in Liver Transplantation was established to collect data on these patients, their tumors, and their treatment. The registry mails out new patient registration forms and patient follow-up forms twice yearly to all known liver transplant programs. Fifty-three programs in 21 countries have supplied information on 553 patients with tumors. Four hundred ten patients had hepatocellular carcinoma (HCC), and 12 had the fibrolamellar variant of HCC (FLL-HCC). These 422 patients were investigated for this study. One hundred sixty-nine of these (40.0%) were classified as "incidental tumors." For the remaining patients, the tumor was known before the transplant. Twenty-six and eight tenths percent of the patients had a history of hepatitis B and 32.7% had a history of hepatitis C. One hundred ninety patients (46.7%) have died, 99 free of tumor and 91 with tumor. Death was tumor related in 90 patients. Of the 232 patients now living, 215 are free of tumor and 17 have tumor. The most common sites for recurrence are the transplanted liver (41.7%) and the lungs (28.7%). The overall patient survival was 72.2% at 1 year, 63.4% at 2 years, 47.4% at 4 years, and 44.4% at 5 years. Using univariate analysis, incidental tumors (p = 0.3107), FLL-HCC (p = 0.0704), multifocal tumor (p = 0.5464), and bilobar tumor (p = 0.1024) were not found to have an influence on patient survival. Four factors, tumor size greater than 5 cm (p = 0.0221), vascular invasion (p = 0.0005), positive nodes (p = 0.0014), and histologic grade (p = 0.0001) had a profound impact on patient survival. Using Cox multiple regression analysis, only histologic grade had a negative impact on overall patient survival (p = 0.0009) and for patients with known tumors (p = 0.0003). For incidental tumors, patient survival was negatively influenced by multifocality (p = 0.0021) and an age older than 60 years (p = 0.0008). Tumor histologic grade (p = 0.0134) and size (>5 cm) (p = 0.0133) were significantly linked to recurrence-free patient survival. This analysis has documented three tumor characteristics that strongly impact patient survival after transplantation for HCC. In addition to tumor size greater than 5 cm and the presence of vascular invasion (which confirm several, single-center studies), this registry notes that a poorly differentiated HCC may be a contraindication for transplantation. A liver tumor's histologic grade may be important information to have when these patients are considered for liver transplantation.

MeSH Terms
Adolescent Adult Aged Carcinoma, Hepatocellular/mortality,pathology,surgery Child Child, Preschool Female Humans Liver Neoplasms/mortality,surgery Liver Transplantation Male Middle Aged Neoplasm Recurrence, Local/epidemiology Registries Survival Rate Treatment Outcome
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Klintmalm G B
Department of Surgery, Baylor University Medical Center, Dallas, Texas 75246, USA.
References (28)
28 references, click to expand
  1. Hepatic transplantation for primary and metastatic cancers of the liver.
    Surgery. 1991 Oct;110(4):726-34; discussion 734-5 PMID: 1656538
  2. Is liver transplantation justified for the treatment of hepatic malignancies?
    Arch Surg. 1990 Oct;125(10):1261-6; discussion 1266-8 PMID: 2171452
  3. Primary treatment of hepatocellular carcinoma by arterial chemoembolization.
    Am J Surg. 1992 Apr;163(4):387-94 PMID: 1373044
  4. Disease recurrence following liver transplantation.
    Am J Surg Pathol. 1990;14 Suppl 1:79-91 PMID: 2109546
  5. Hepatic cryosurgery.
    Surg Clin North Am. 1989 Apr;69(2):433-40 PMID: 2648623
  6. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence.
    Ann Surg. 1989 Jan;209(1):88-98 PMID: 2535924
  7. Liver transplantation for malignant disease. Results in 93 consecutive patients.
    Ann Surg. 1988 Apr;207(4):373-9 PMID: 2451484
  8. Is there a place for liver grafting for malignancy?
    Transplant Proc. 1988 Feb;20(1 Suppl 1):478-82 PMID: 2450417
  9. Role of liver transplantation in cancer therapy.
    Ann Surg. 1985 Oct;202(4):401-7 PMID: 2996449
  10. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.
    Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 PMID: 9409568
  11. Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
    Liver Transpl Surg. 1995 Jul;1(4):242-8 PMID: 9346574
  12. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.
    Hepatology. 1997 Oct;26(4):877-83 PMID: 9328308
  13. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study.
    Hepatology. 1997 Aug;26(2):444-50 PMID: 9252157
  14. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery.
    Ann Surg. 1997 Jul;226(1):43-50 PMID: 9242336
  15. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis.
    J Hepatol. 1997 Jun;26(6):1274-80 PMID: 9210614
  16. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.
    Hepatology. 1997 Jun;25(6):1485-9 PMID: 9185772
  17. DNA flow cytometry in patients undergoing liver transplantation for hepatocellular carcinoma.
    Transpl Int. 1996;9 Suppl 1:S112-4 PMID: 8959805
  18. Liver transplantation for hepatocellular carcinoma: prognostic factors associated long-term survival.
    Transpl Int. 1996;9 Suppl 1:S109-11 PMID: 8959804
  19. Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection?
    Cancer. 1992 Nov 1;70(9):2263-7 PMID: 1327495
  20. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients.
    Gastroenterology. 1993 Jan;104(1):196-202 PMID: 8380393
  21. Current treatment modalities for hepatocellular carcinoma.
    Ann Surg. 1994 Mar;219(3):236-47 PMID: 8147605
  22. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation.
    Radiology. 1994 Sep;192(3):687-90 PMID: 8058934
  23. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma.
    Am J Gastroenterol. 1995 Jan;90(1):29-34 PMID: 7801944
  24. Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma.
    Hepatology. 1995 Feb;21(2):403-7 PMID: 7843713
  25. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis.
    J Am Coll Surg. 1995 May;180(5):596-603 PMID: 7749537
  26. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
    Ann Surg. 1995 Jun;221(6):734-41; discussion 731-43 PMID: 7794077
  27. Liver transplantation for hepatocellular carcinoma: consideration from the findings on autopsy.
    Transplant Proc. 1996 Jun;28(3):1691-2 PMID: 8658842
  28. Orthotopic liver transplantation for hepatocellular carcinoma. Factors affecting long-term patient survival.
    Arch Surg. 1996 Sep;131(9):935-9; discussion 939-41 PMID: 8790178
Article Info
Journal
Annals of surgery
Abbr.
Ann Surg
ISSN
0003-4932
Published
1998-10-00
Pages
479-90
Language
English
Region
United States
NLM ID
0372354
PMCID
PMC1191521
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com